Stocks › KURA

Kura Oncology, Inc.

KURA·Nasdaq·United States United States·USD
$6.91
-0.44 (-5.99%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
KURA
Kura Oncology, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
KURAS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of KURA by members of U.S. Congress · 1 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Christopher L. JacobsChristopher L. JacobsHouse · R · NY KURAKura Oncology, Inc. · Stock Purchase
$1,001 - $15,000
Jan 20, 2023 Dec 12, 2022 Filing ↗

Whale Activity

Position changes in KURA reported for 2026-09-30 by 254 institutional filers
Increased: 83New: 35Held: 31Decreased: 71Closed: 23No prior filing: 11
  • Increased83
  • New35
  • Held31
  • Decreased71
  • Closed23
  • No prior filing11
FilerSharesValueChange
BlackRock, Inc.11.8M$125.9Mincreased
MONTANOVA CAPITAL, LLC7.9M$84.6Mdecreased
BVF INC/IL6.7M$71.7Mdecreased
STATE STREET CORP4.7M$50.4Mdecreased
VANGUARD CAPITAL MANAGEMENT LLC3.9M$41.8Mdecreased
AQR CAPITAL MANAGEMENT LLC3.7M$39.5Mincreased
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP2.8M$29.5Mincreased
GEODE CAPITAL MANAGEMENT, LLC2.3M$24.6Mincreased
ALETHEA CAPITAL MANAGEMENT, LLC2.2M$23.3Mincreased
ARMISTICE CAPITAL, LLC2.1M$22.4Mdecreased
RENAISSANCE TECHNOLOGIES LLC2.0M$21.5Mincreased
GOLDMAN SACHS GROUP INC2.0M$21.2Mdecreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by KURA insiders, by quarter · Form 4
-200.0K-100.0K0100.0K200.0K2025 Q1: -45.4K2025 Q12025 Q2: -3,1172025 Q22025 Q3: 21.9K2025 Q32025 Q4: -78.3K2025 Q42026 Q1: -36.1K2026 Q12026 Q2: -99.8K2026 Q22026 Q3: 46.1K2026 Q32026 Q4: 109.8K2026 Q4

Recent Insider Transactions

237 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Powl Brian T.Chief Commercial Officer Sale −448 $7.27 $3K Nov 19, 2026 Form 4 ↗
Leoni MollieChief Medical Officer Sale −22.2K $7.45 $166K Nov 17, 2026 Form 4 ↗
Powl Brian T.Chief Commercial Officer Sale −15.3K $7.45 $114K Nov 17, 2026 Form 4 ↗
FORD KATHLEENChief Operating Officer Sale −3,668 $7.46 $27K Nov 17, 2026 Form 4 ↗
DOYLE THOMAS JAMESSVP, Finance & Accounting Sale −4,697 $7.44 $35K Nov 16, 2026 Form 4 ↗
Leoni MollieChief Medical Officer Sale −19.0K $7.44 $141K Nov 16, 2026 Form 4 ↗
Powl Brian T.Chief Commercial Officer Sale −9,196 $7.44 $68K Nov 16, 2026 Form 4 ↗
Bair Teresa BrophyChief Legal Officer Sale −8,601 $7.44 $64K Nov 16, 2026 Form 4 ↗
FORD KATHLEENChief Operating Officer Sale −7,042 $7.44 $52K Nov 16, 2026 Form 4 ↗
WILSON TROY EDWARDPresident and CEO · Director Purchase Amended +101.1K $7.42 $750K Nov 16, 2026 Form 4 ↗
WILSON TROY EDWARDPresident and CEO · Director Purchase +101.1K $7.42 $750K Nov 16, 2026 Form 4 ↗
WILSON TROY EDWARDPresident and CEO · Director Purchase Amended +98.9K $7.63 $754K Nov 13, 2026 Form 4 ↗
WILSON TROY EDWARDPresident and CEO · Director Purchase +98.9K $7.63 $754K Nov 13, 2026 Form 4 ↗
FORD KATHLEENChief Operating Officer Sale −3,668 $10.75 $39K Sep 29, 2026 Form 4 ↗
Leoni MollieChief Medical Officer Sale −28.8K $10.75 $310K Sep 29, 2026 Form 4 ↗
Powl Brian T.Chief Commercial Officer Sale −15.4K $10.75 $166K Sep 29, 2026 Form 4 ↗
Bair Teresa BrophyChief Legal Officer Sale −8,442 $10.50 $89K Sep 28, 2026 Form 4 ↗
FORD KATHLEENChief Operating Officer Sale −6,906 $10.50 $73K Sep 28, 2026 Form 4 ↗
Leoni MollieChief Medical Officer Sale −12.4K $10.50 $131K Sep 28, 2026 Form 4 ↗
DOYLE THOMAS JAMESSVP, Finance & Accounting Sale −4,607 $10.50 $48K Sep 28, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding KURA · SEC Form N-PORT
FundSharesValue% of fundAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF
SPDR SERIES TRUST
3.1M$34.1M0.32%Jun 30, 2026
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
2.8M$30.7M0.00%Jun 30, 2026
iShares Russell 2000 ETF
iShares Trust
2.2M$24.3M0.03%Jun 30, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
1.0M$11.3M0.01%Jun 30, 2026
iShares Russell 2000 Growth ETF
iShares Trust
785.1K$8.6M0.06%Jun 30, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
929.0K$8.4M0.02%Jul 31, 2026
BlackRock Advantage Small Cap Core Fund
BlackRock Funds
526.6K$6.7M0.12%Aug 31, 2026
iShares Biotechnology ETF
iShares Trust
606.1K$6.6M0.07%Jun 30, 2026
VANGUARD RUSSELL 2000 INDEX FUND
VANGUARD SCOTTSDALE FUNDS
488.0K$6.2M0.03%Aug 31, 2026
Fidelity Extended Market Index Fund
Fidelity Concord Street Trust
442.4K$5.6M0.01%Aug 31, 2026

Mutual funds and ETFs whose N-PORT filings list KURA's shares (CUSIP 50127T109), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • BVF INC/ILSCHEDULE 13G/A · passive (13G) · 6.7M shares7.5%
    Nov 16, 2026 · ↗
  • BVF PARTNERS L P/ILSCHEDULE 13G/A · passive (13G) · 6.7M shares7.5%
    Nov 16, 2026 · ↗
  • BVF GP HOLDINGS LLCSCHEDULE 13G/A · passive (13G) · 6.1M shares6.9%
    Nov 16, 2026 · ↗
  • BVF Partners OS Ltd.SCHEDULE 13G/A · passive (13G) · 443.4K shares0.5%
    Nov 16, 2026 · ↗
  • Biotechnology Value Trading Fund OS LPSCHEDULE 13G/A · passive (13G) · 443.4K shares0.5%
    Nov 16, 2026 · ↗
  • BVF II GP LLCSCHEDULE 13G/A · passive (13G) · 2.6M shares2.9%
    Nov 16, 2026 · ↗
  • BIOTECHNOLOGY VALUE FUND II LPSCHEDULE 13G/A · passive (13G) · 2.6M shares2.9%
    Nov 16, 2026 · ↗
  • BVF I GP LLCSCHEDULE 13G/A · passive (13G) · 3.5M shares3.9%
    Nov 16, 2026 · ↗
  • LAMPERT MARK NSCHEDULE 13G/A · passive (13G) · 6.7M shares7.5%
    Nov 16, 2026 · ↗
  • BIOTECHNOLOGY VALUE FUND L PSCHEDULE 13G/A · passive (13G) · 3.5M shares3.9%
    Nov 16, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming Kura Oncology, Inc. as client

No lobbying filings found naming Kura Oncology, Inc. as the client.

Government Contracts

Federal awards to Kura Oncology, Inc. · USAspending

No federal contract awards found for Kura Oncology, Inc..

U.S. Patents

Recent USPTO applications naming Kura Oncology, Inc.

No USPTO patent applications found for Kura Oncology, Inc..

Annual Financials

From KURA's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$67.5M$53.9M$0n/an/a
Operating income-$303.6M-$193.2M-$165.8M-$139.9Mn/a
Net income-$278.7M-$174.0M-$152.6M-$135.8M-$130.5M
Diluted EPS-$3.18-$2.02-$2.08-$2.03-$1.97
Operating cash flow-$64.1M$134.3M-$124.8M-$110.1M-$104.6M
Cash and equivalents$149.1M$224.5M$37.3M$51.8M$90.7M
Total assets$738.4M$760.2M$448.9M$456.3M$534.1M
Total liabilities$564.2M$346.5M$51.7M$36.0M$27.4M
Shareholders' equity$174.1M$413.6M$397.3M$420.3M$506.6M

As Kura Oncology, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 5, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in KURA's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 10, 2026
    EDGAR ↗
  • 8-K · Items 8.01Other eventsSep 9, 2026
    EDGAR ↗
  • 8-K · Items 5.02Officer / director changeSep 8, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 12, 2026
    EDGAR ↗
  • 8-K · Items 5.02Officer / director changeJul 29, 2026
    EDGAR ↗
  • 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteJun 4, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsMay 12, 2026
    EDGAR ↗

About Kura Oncology, Inc.

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersSAN DIEGO, CA
IncorporatedDE
Former namesZETA ACQUISITION CORP III